UK Ibrance Patient Program (IPP) Study (ROIS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03921866|
Recruitment Status : Not yet recruiting
First Posted : April 19, 2019
Last Update Posted : May 24, 2019
|Condition or disease||Intervention/treatment|
|HR+/HER2- Locally Advanced, Metastatic Breast Cancer||Drug: Palbociclib|
Hormone receptor positive (HR+) breast cancer (BC) represents the largest therapeutic subtype of the disease, accounting for 60 to 65% of all malignant neoplasms of the breast. Palbociclib (Ibrance®) is a small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) which in clinical trial settings has been shown to increase progression-free survival (PFS) for patients with HR+, human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC). Palbociclib first received a European Union (EU) marketing authorisation in September 2016, to be commercialised as Ibrance® by Pfizer. Palbociclib was recommended for use with an aromatase inhibitor in patients with HR+/HER2- locally advanced and MBC in the National Health Service (NHS) in England by the National Institute for Health and Care Excellence (NICE) in November 2017 and by the Scottish Medicines Consortium (SMC) in December 2017. In order to provide access to palbociclib in the United Kingdom (UK) during the NICE/SMC appraisal period, the Ibrance® Patient Program (IPP) was initiated and run by Pfizer between April 2017 until a positive NICE/SMC appraisal in November 2017 (for England and Wales) or December 2017 (for Scotland).
Pfizer are interested in the opportunity to collect data from patients who received palbociclib as part of the UK IPP, to better understand patients' characteristics in a routine care setting, treatment persistence and dose management, clinical outcomes, and healthcare resource utilisation. This study will provide real-world evidence on patients' clinical progression and experience of treatment with palbociclib in routine clinical settings in a UK context.
What are the real-world treatment patterns, patients' characteristics, clinical outcomes and healthcare resource utilisation associated with palbociclib treatment in the 3 years following initiation in United Kingdom patients with HR+/HER2- MBC treated as part of the IPP?
|Study Type :||Observational|
|Estimated Enrollment :||250 participants|
|Official Title:||Observational Cohort Study of Patients With Hormone Receptor-positive Metastatic Breast Cancer Treated With Palbociclib (Ibrance(Registered)) as Part of the United Kingdom Ibrance (Registered) Patient Program (IPP); the Real Outcomes Ibrance (Registered) Study (ROIS)|
|Estimated Study Start Date :||May 2019|
|Estimated Primary Completion Date :||December 1, 2021|
|Estimated Study Completion Date :||December 1, 2021|
- Drug: Palbociclib
- Clinical characteristics [ Time Frame: 36 months ]To describe patient demographic and clinical characteristics at initiation of palbociclib.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03921866
|Contact: Pfizer CT.gov Call Center||1-800-718-1021||ClinicalTrials.gov_Inquiries@pfizer.com|
|Brigton and Sussex||Not yet recruiting|
|Brighton, United Kingdom|
|Beatson||Not yet recruiting|
|Glasgow, United Kingdom|
|Liverpool||Not yet recruiting|
|Liverpool, United Kingdom|
|Guys and St Thomas'||Not yet recruiting|
|London, United Kingdom|
|Maidstone Hospital||Not yet recruiting|
|Maidstone, United Kingdom|
|Christie||Not yet recruiting|
|Manchester, United Kingdom|
|Newcastle||Not yet recruiting|
|Newcastle, United Kingdom|
|Truro||Not yet recruiting|
|Truro, United Kingdom|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|